<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease is a <z:hpo ids='HP_0011010'>chronic</z:hpo> relapsing form of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> affecting multiple organs </plain></SENT>
<SENT sid="1" pm="."><plain>Central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement is a common presentation </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) is considered to play a major role in the disease pathogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a patient with a long history of neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease who showed a remarkable response to infliximab therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Given the variable and limited success of other interventions, the use of anti-TNF-alpha therapy seems to be effective for patients with refractory disease </plain></SENT>
</text></document>